CLC Number:
- R473.73
| [1] Hashmi1 H, Husnain M, Khan A, et al. CD38-Directed Therapies for Management of Multiple Myeloma[J].ImmunoTargets and Ther,2021,10:201-211.DOI:10.2147/ITT.S259122. [2] Cáceres MC, Guerrero-Martín J, Pérez-Civantos D, et al.The Importance of Early Identification of Infusion-related Reactions to Monoclonal Antibodies[J].Ther Clin Risk Manag, 2019, 15:965-977. DOI:10.2147/TCRM.S204909. [3] 付恩锋,王艳,王洁.70例非小细胞肺癌患者免疫检查点抑制剂不良反应分析及护理对策[J].护理学报,2020, 27(14):68-70. DOI: 10.16460/j.issn1008-9969.2020.14.068. [4] 薛静,张丽燕.消化道肿瘤患者免疫检查点抑制剂治疗所致不良反应的护理[J].护理学报,2019,26(13):63-65.DOI:10.16460/j.issn1008-9969.2019.13.063. [5] 陈仙红,钱颖,阮佳音.达雷木单抗治疗复发难治性多发性骨髓瘤患者的观察和护理[J].天津护理,2021,29(3):323-325. DOI:10.3969/j.issn.1006-9143.2021.03.021. [6] King T, Jagger J, Wood J, et al.Best Practice for the Administration of Daratumumab in Multiple Myeloma[J]. Australian Myeloma Nurse Expert Opinion Asia Pac J Oncol Nurs, 2018,5(3):270-281. DOI:10.4103/apjon.apjon_9_18. [7] Barr H, Dempsey J, Waller A, et al.Ninety-minute Daratumumab Infusion is Safe in Multiple Myeloma[J]. Leukemia,2018,32(11):2495-2518. DOI:10.1038/s41375-018-0120-2. [8] Lokhorst HM, Plesner T, Laubach JP, et al.Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma[J]. N Engl J Med, 2015,373(13):1207-1219.DOI:10.1056/NEJMoa1506348. [9] Moore DC, Arnall JR, Thompson DL, et al.Evaluation of Montelukast for the Prevention of Infusion-related Reactions with Daratumumab[J].Clin Lymphoma Myeloma Leuk, 2020, 20(10):e777-e781. DOI:10.1016/j.clml.2020.05.024. |
| [1] | CAO Min, ZHANG Pei-li, HOU Xiao-ya, GAO Chao-yue, GUO Lin-fang, LI Ying. Nutritional care experience of caregivers of colorectal cancer patients undergoing chemotherapy based on ABC-X model: a qualitative study [J]. Journal of Nursing, 2025, 32(2): 13-18. |
| [2] | LIU Qi, LIU Jia-li, LIU Yu, YANG Li-min, FAN Yu-ying, LV Xing, JIN Hui-ying. Physical-psychological symptom burden trajectories and influencing factors in nasopharyngeal carcinoma patients during induction chemotherapy plus concurrent chemoradiotherapy [J]. Journal of Nursing, 2025, 32(1): 1-6. |
| [3] | . [J]. Journal of Nursing, 2025, 32(1): 39-43. |
| [4] | YAO Wan-qing, YANG Li-zhuang, CHEN Dan-dan, ZHANG Wan-qiu, LU Wei, GUAN Cui-hong, LI Hai. Efficacy of different non-drug interventions on cancer-related fatigue in breast cancer patients: a network Meta-analysis [J]. Journal of Nursing, 2024, 31(24): 37-43. |
| [5] | DAI Qian, LIU Xiang-yu, ZHU Xiao-mei, WANG Jia-li, HUANG Yuan-si. Status quo of self-compassion in patients with colorectal cancer stoma and its influencing factors [J]. Journal of Nursing, 2024, 31(23): 13-17. |
| [6] | . [J]. Journal of Nursing, 2024, 31(22): 73-78. |
| [7] | LI Yue-ge, KONG Han, CAO Ding, LI Jia-xin, SHANG Ya-meng, CHANG Shu-ying. Current status of fear of cancer recurrence in young and middle-aged patients with cervical cancer after surgery and its influencing factors: a 228-case study [J]. Journal of Nursing, 2024, 31(20): 8-12. |
| [8] | . [J]. Journal of Nursing, 2024, 31(20): 19-23. |
| [9] | . [J]. Journal of Nursing, 2024, 31(20): 29-32. |
| [10] | . [J]. Journal of Nursing, 2024, 31(18): 30-34. |
| [11] | GENG Yu-fang, QIN Ru-meng, WANG Hui, ZHANG Shan-shan, ZHOU Li-hua. Construction of post-traumatic growth model of ovarian cancer patients based on interpretative phenomenological analysis [J]. Journal of Nursing, 2024, 31(18): 73-78. |
| [12] | . [J]. Journal of Nursing, 2024, 31(17): 51-56. |
| [13] | YU Feng, SUN Li, HU De-ying, HU Jie, WANG Jia-qing, LV Chu-feng. Competency model of suicide gatekeeper for oncology nurses based on behavioral event interview and expert consultation [J]. Journal of Nursing, 2024, 31(17): 73-78. |
| [14] | . [J]. Journal of Nursing, 2024, 31(16): 56-61. |
| [15] | ZHANG Shu-zhen, YU Wen-ru, ZHANG Jun-feng, JIANG Jia-yao, LUO Mei, LIN Bi-yu, MAI Min-wen, YANG Meng-ting. Evidence-based nursing practice in prevention and management of radiation dermatitis in cancer patients undergoing radiotherapy [J]. Journal of Nursing, 2024, 31(16): 62-66. |
|
||